Pharmaceuticals - Global Group of Eight (G8) Industry Guide

Pharmaceuticals - Global Group of Eight (G8) Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry in each of the G8 (United States, Canada, Germany, France, United Kingdom, Italy, Russia and Japan) countries. The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market.

Scope of the Report

• Contains an executive summary and data on value, volume and segmentation
• Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies
• Incorporates in-depth five forces competitive environment analysis and scorecards
• Compares data from the US, Canada, Germany, France, UK, Italy, Russia and Japan, alongside individual chapters on each country. .
• Includes a five-year forecast of the industry

Highlights

The G8 countries contributed $534.8 billion in 2011 to the global pharmaceuticals industry, with a compound annual growth rate (CAGR) of 3.3% between 2007 and 2011.

The G8 countries are expected to reach a value of $600.2 billion in 2016, with a CAGR of 2.3% over the 2011-16 period.

Among the G8 countries, the US holds the major share of the pharmaceuticals industry. It accounted for a share of 49.1% in 2011

Among the G8 nations, the US is the leading country in the pharmaceuticals industry, with market revenues of $262.7 billion in 2011.

The US is expected to lead the pharmaceuticals industry in the G8 nations with a value of $299.5 billion in 2016

Why you should buy this report

• Spot future trends and developments
• Inform your business decisions
• Add weight to presentations and marketing materials
• Save time carrying out entry-level research

Market Definition

The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.

Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors).

Any currency conversions used in the production of this report have been calculated at constant 2011 annual average exchange rates.